Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of medicines worldwide.
Undervalued with reasonable growth potential.
Share Price & News
How has Almirall's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALM's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ALM underperformed the Spanish Pharmaceuticals industry which returned 19.2% over the past year.
Return vs Market: ALM underperformed the Spanish Market which returned -19.4% over the past year.
Price Volatility Vs. Market
How volatile is Almirall's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StResults: Almirall, S.A. Beat Earnings Expectations And Analysts Now Have New Forecasts
3 weeks ago | Simply Wall StWhat Type Of Shareholder Owns Almirall, S.A.'s (BME:ALM)?
1 month ago | Simply Wall StThese 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well
Is Almirall undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ALM (€11.94) is trading below our estimate of fair value (€19.55)
Significantly Below Fair Value: ALM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ALM is good value based on its PE Ratio (17x) compared to the Pharmaceuticals industry average (23.3x).
PE vs Market: ALM is poor value based on its PE Ratio (17x) compared to the Spanish market (15.8x).
Price to Earnings Growth Ratio
PEG Ratio: ALM is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: ALM is good value based on its PB Ratio (1.5x) compared to the XE Pharmaceuticals industry average (3.3x).
How is Almirall forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALM's forecast earnings growth (20.8% per year) is above the savings rate (1.3%).
Earnings vs Market: ALM's earnings (20.8% per year) are forecast to grow faster than the Spanish market (17.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ALM's revenue (8.1% per year) is forecast to grow faster than the Spanish market (5.1% per year).
High Growth Revenue: ALM's revenue (8.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALM's Return on Equity is forecast to be low in 3 years time (10.5%).
How has Almirall performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALM has high quality earnings.
Growing Profit Margin: ALM's current net profit margins (13.9%) are higher than last year (10.1%).
Past Earnings Growth Analysis
Earnings Trend: ALM's earnings have declined by -39.8% per year over the past 5 years.
Accelerating Growth: ALM's earnings growth over the past year (51.8%) exceeds its 5-year average (-39.8% per year).
Earnings vs Industry: ALM earnings growth over the past year (51.8%) exceeded the Pharmaceuticals industry 7%.
Return on Equity
High ROE: ALM's Return on Equity (9%) is considered low.
How is Almirall's financial position?
Financial Position Analysis
Short Term Liabilities: ALM's short term assets (€421.7M) exceed its short term liabilities (€256.2M).
Long Term Liabilities: ALM's short term assets (€421.7M) do not cover its long term liabilities (€781.7M).
Debt to Equity History and Analysis
Debt Level: ALM's debt to equity ratio (34.1%) is considered satisfactory.
Reducing Debt: ALM's debt to equity ratio has increased from 22.4% to 34.1% over the past 5 years.
Debt Coverage: ALM's debt is well covered by operating cash flow (64.6%).
Interest Coverage: ALM's interest payments on its debt are well covered by EBIT (10.1x coverage).
What is Almirall's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ALM's dividend (1.68%) isn’t notable compared to the bottom 25% of dividend payers in the Spanish market (2.61%).
High Dividend: ALM's dividend (1.68%) is low compared to the top 25% of dividend payers in the Spanish market (7.43%).
Stability and Growth of Payments
Stable Dividend: ALM's dividend payments have been volatile in the past 10 years.
Growing Dividend: ALM's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (28.5%), ALM's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: ALM's dividends in 3 years are forecast to be well covered by earnings (29.9% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Peter Guenter (57yo)
Mr. Peter Guenter serves as Member of Supervisory Board at Galapagos NV since April 28, 2020. He has been Chairman of Management Board and Chief Executive Officer at Almirall, S.A. since August 28, 2017 an ...
|Chairman & President||no data||€455.00k||no data|
|CEO, Chairman of Management Board & Executive Director||2.75yrs||no data||no data|
|General Counsel||no data||no data||no data|
|Secretary & Non-Voting Director||no data||no data||no data|
|Member of Global Advisory Board-Spain||11.33yrs||no data||no data|
|External Independent Director||7.58yrs||€122.00k||no data|
|Independent Vice Chairman||no data||€132.00k||no data|
|External Independent Director||7.33yrs||€122.00k||no data|
|External Director||5.83yrs||€50.00k||no data|
|External Director||5.83yrs||€50.00k||0.00057% €11.8k|
Experienced Board: ALM's board of directors are considered experienced (6.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Almirall, S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Almirall, S.A.
- Ticker: ALM
- Exchange: BME
- Founded: 1943
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €2.068b
- Shares outstanding: 174.55m
- Website: https://www.almirall.com
Number of Employees
- Almirall, S.A.
- Ronda General Mitre, 151
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALM||BME (Bolsas y Mercados Espanoles)||Yes||Common Stock||ES||EUR||Jun 2007|
|E2Z||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2007|
|0O9B||LSE (London Stock Exchange)||Yes||Common Stock||GB||EUR||Jun 2007|
|LBTS.F||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Jun 2007|
|ALME||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Stock||GB||EUR||Jun 2007|
Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, acne, rosacea, and psoriasis; and central nervous system, cardiovascular, and gastrointestinal diseases. Its strategic brands include ACTIKERALL, BALNEUM, DECODERM, SATIVEX, SKILARENCE, and DECODERM. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases, as well as drug discovery partnership with X-Chem, Inc.; and a research collaboration with Iktos in the area of artificial intelligence for new drug design. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/29 22:34|
|End of Day Share Price||2020/05/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.